<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04317404</url>
  </required_header>
  <id_info>
    <org_study_id>STU 2019-1202</org_study_id>
    <nct_id>NCT04317404</nct_id>
  </id_info>
  <brief_title>Knee Steroid Injection and Blood Sugar Signatur</brief_title>
  <official_title>Identifying Variables Associated With Steroid-Induced Hyperglycemia Following Intra-articular Knee Injections Among Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Foundation for Physical Medicine and Rehabilitation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, observational study assessing the relationship between HbA1c level and the
      post-injection blood glucose signature. Participants will be non-diabetic, pre-diabetic,
      non-insulin dependent and insulin dependent type 2 diabetic patients who will be receiving a
      knee steroid injection. All of them will be consented a week prior to the injection, when the
      CGM sensor will be applied to the back of the upper arm. This will be removed a week after
      the injection. KOOS survey as well as VAS will be administered. Adverse events (e.g., change
      in medication or hospitalization) will be monitored throughout the study.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Post-injection glucose levels</measure>
    <time_frame>1 week</time_frame>
    <description>Blood glucose levels after injection of steroid to the knee</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-injection adverse events</measure>
    <time_frame>1 week</time_frame>
    <description>Adverse events after injection of steroid to the knee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KOOS Knee survey</measure>
    <time_frame>2 weeks</time_frame>
    <description>KOOS Knee survey administered before and after steroid injection to the knee</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Diabetes</condition>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Diabetic with Knee Osteoarthritis</arm_group_label>
    <description>HbA1c between 6.5% - 12.0% in the 3 months prior to Visit 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-diabetic with Knee Osteoarthritis</arm_group_label>
    <description>HbA1c between 5.6% - 6.4% in the 3 months prior to Visit 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-diabetic with Knee Osteoarthritis</arm_group_label>
    <description>HbA1c &lt; 5.6% in the 3 months prior to Visit 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>40 mg Triamcinolone acetonide</intervention_name>
    <description>Unilateral knee steroid injection</description>
    <arm_group_label>Diabetic with Knee Osteoarthritis</arm_group_label>
    <arm_group_label>Non-diabetic with Knee Osteoarthritis</arm_group_label>
    <arm_group_label>Pre-diabetic with Knee Osteoarthritis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Knee joint osteoarthritis requiring knee joint steroid injection
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients at the Parkland Outpatient Clinic

          -  Indication for unilateral knee joint steroid injection for the treatment of knee joint
             osteoarthritis

        Exclusion Criteria:

          -  Less than 18 years old

          -  HbA1c &gt; 12.0%

          -  steroid exposure in the 3 months prior to Visit 1

          -  3 or more steroid injections in the preceding 12 months

          -  known contraindication to steroid injection (adverse reaction or allergy, active
             infection, INR &gt; 3.0)

          -  lack of improvement with prior knee steroid injection

          -  change in diabetic medication regimen in the last 1 month

          -  significant change in diet within the last 1 month

          -  current use of aspirin

          -  allergy to adhesive

          -  planned MRI, XR, or CT during the 2-week study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Reed Williams, MD</last_name>
    <phone>2146482240</phone>
    <email>Reed.Williams@UTSouthwestern.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Parkland Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 19, 2020</study_first_submitted>
  <study_first_submitted_qc>March 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2020</study_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

